Recently, Collina F. et al. demonstrated a key role of AXL/AKT/NF-kB in the RAI refractoriness and disease persistence or recurrence of thyroid cancer, especially when combined with BRAF mutations [11]. This evidence concerns the gene AKT1 and thyroid gland carcinoma.